STAAR Surgical Company

Equities

STAA

US8523123052

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 21:00:00 16/07/2024 BST			5-day change	1st Jan Change
45.83 ^USD	+1.35%		+10.51%	+46.84%

07-16	North American Morning Briefing : Retail Sales, -2-	DJ
07-15	Medical Technology Companies Poised for Another 'Solid' Quarter, Morgan Stanley Says	MT

STAAR Surgical Company Announces Board Appointments

January 26, 2021 at 03:45 pm

STAAR Surgical Company announced the appointments of Elizabeth Yeu, M.D., Partner, Virginia Eye Consultants, and K. Peony Yu, M.D., retired Chief Medical Officer, FibroGen Inc., to its Board of Directors, effective January 21, 2021. The other current members of STAAR’s Board of Directors include Stephen Farrell, Thomas Frinzi, Gilbert Kliman, M.D., Caren Mason, and Louis Silverman.

Latest news about STAAR Surgical Company

North American Morning Briefing : Retail Sales, -2-	07-16	DJ
Medical Technology Companies Poised for Another 'Solid' Quarter, Morgan Stanley Says	07-15	MT
Morgan Stanley Downgrades STAAR Surgical to Underweight From Equalweight, Cuts Price Target to $37 From $50	07-15	MT
STAAR Surgical Company Provides Information to the Shareholders	06-21	CI
Transcript : STAAR Surgical Company Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:00 AM	06-12
BTIG Upgrades STAAR Surgical to Buy From Neutral, Price Target is $46	06-11	MT
Mizuho Adjusts STAAR Surgical's Price Target to $55 From $53, Keeps Buy Rating	05-08	MT
Morgan Stanley Raises Price Target on STAAR Surgical to $50 From $35, Keeps Equalweight Rating	05-08	MT
Transcript : STAAR Surgical Company, Q1 2024 Earnings Call, May 07, 2024	05-07
STAAR Surgical Company Reports Earnings Results for the First Quarter Ended March 29, 2024	05-07	CI
STAAR Surgical Company Reiterates Earnings Guidance for the Fiscal Year 2024	05-07	CI
STAAR Surgical Company Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision	05-07	CI
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel	05-01	CI
Mizuho Adjusts Price Target on STAAR Surgical to $53 From $45, Maintains Buy Rating	04-11	MT
Canaccord Genuity Raises Price Target on STAAR Surgical to $46 From $32, Maintains Hold Rating	04-08	MT
STAAR Surgical Shares Jump After Reporting Preliminary Fiscal Q1 Sales	04-04	MT
Sector Update: Health Care Stocks Lean Higher Pre-Bell Thursday	04-04	MT
STAAR Surgical Reports Preliminary Fiscal Q1 Sales; Updates Fiscal 2024 Sales Outlook -- Shares Jump Pre-Bell	04-04	MT
STAAR Surgical Company Provides Sales Guidance for the First Quarter Ended March 29, 2024	04-04	CI
STAAR Surgical Unveils New EVO ICL Data and Latest Innovation for 2024	04-02	CI
STAAR Surgical Company Announces Board Changes	03-12	CI
North American Morning Briefing : Inflation Data -2-	03-12	DJ
Stifel Upgrades STAAR Surgical to Buy From Hold, Raises Price Target to $50 From $30	03-11	MT
Mizuho Securities Adjusts Price Target on STAAR Surgical to $45 From $50, Keeps Buy Rating	02-28	MT
Piper Sandler Cuts STAAR Surgical Price Target to $33 From $40, Maintains Neutral Rating	02-27	MT

Chart STAAR Surgical Company

Duration

Period

More charts

Company Profile

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. These lenses provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. The Company is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. The Company markets and sells ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. The Companyâs EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company also markets and sells an ICL lens to treat hyperopia (farsightedness), which is called Visian ICL.

Sector

Medical Equipment, Supplies & Distribution

Calendar

30/07/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for STAAR Surgical Company

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

45.83 USD

Average target price

51.22 USD

Spread / Average Target

+11.76%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
STAAR SURGICAL COMPANY	+46.84%	2.25B
ABBOTT LABORATORIES	-6.68%	179B
MEDTRONIC PLC	-5.20%	100B
BECTON, DICKINSON AND COMPANY	-5.38%	66.67B
HOYA CORPORATION	+18.16%	44.81B
DEXCOM, INC.	-6.47%	46.16B
CENCORA, INC.	+9.74%	44.38B
METTLER-TOLEDO INTERNATIONAL, INC.	+14.01%	29.53B
TERUMO CORPORATION	+22.31%	25.83B
WEST PHARMACEUTICAL SERVICES, INC.	-6.53%	23.97B

Other Medical Equipment, Supplies & Distribution